MolMed TK four studies accepted for presentation at ASCO 2013
Region: ItalyMolMed S.p.A. (MLM.MI) today announced that four studies on its investigational therapeutics NGR-hTNF and TK have been accepted for presentation at the 49th ASCO Annual Meeting, that will take place in Chicago (IL, U... more
Views: 230MolMed NGR-hTNF: MolMed Board of Directors approves the interim financial report at 31 March 2013
Region: ItalyThe Board of Directors of MolMed S.p.A. (MLM.MI), chaired by Prof. Claudio Bordignon, today reviewed and approved the interim financial report at 31 March 2013. The most important elements were: progress ... more
Views: 258MolMed TK Shareholders’ Meeting approves the Financial Statements 2012
Region: Italy
MolMed Shareholders’ Meeting approves the Financial Statements 2012 and appoints members of Board of Directors and Board of Statutory AuditorsMeeting of the new Board of Directors: appointment of the Chief Exec... more
Views: 447MolMed TK: Expiry deadline for submitting lists Board of Statutory Auditors
Region: ItalyExpiry of extended deadline for submitting lists for the appointment of the Board of Statutory Auditors: no lists were presented by minority Shareholders With reference to the Shareholders’ Meeting of MolMed S... more
Views: 464MolMed TK: Bod approves draft financial statements for fiscal year 2012
Region: Italy
The Board of Directors of MolMed S.p.A. (MLM.MI), chaired by Professor Claudio Bordignon, today reviewed and approved the draft financial statements at 31 December 2012. The most relevant elements concerning pro... more
Views: 355MolMed acute leukaemias: Contribution of TK presented at the BMT Tandem Meetings
Region: ItalyMolMed S.p.A. (MLM.MI) announces the results of the contribution given by its investigational cell-based therapy TK to the treatment of haematologic malignancies through bone marrow transplantation from par... more
Views: 445Molmed TK ASH: Long term assessment of TK clinical benefit at the 54th Annual Meeting
Region: ItalyMilan (Italy), 10 December 2012 – MolMed S.p.A. (MLM.MI) announces the presentation of the long term clinical benefit and safety data of its investigational cell-based therapy TK at the 54th Annu... more
Views: 607MolMed: BoD approves the interim financial report at 30 September 2012
Region: ItalyMilan (Italy), 12 November 2012 – The Board of Directors of MolMed S.p.A. (MLM.MI), chaired by Prof. Claudio Bordignon, today reviewed and approved the interim financial report at 30 September 2012. The most im... more
Views: 661Molmed: Update on NGR-hTNF presented at ESMO Congress 2012
Region: Italy
MolMed S.p.A. (MLM.MI) presented, at the 37th ESMO Congress, three studies on its investigational biological drug NGR-hTNF, including updated results in non-small cell lung cancer (NSCLC) patients and two retros... more
Views: 529
Member Since: October 2012
Location: Italy
Rating: No Rating
# of Articles: 9
Contact Reporter
